Therapeutic time window of disease‐modifying therapy for early Alzheimer's disease

Therapeutic time window of disease‐modifying therapy for early Alzheimer's disease

Abstract Introduction Recently approved disease‐modifying therapies (DMT) for early Alzheimer's disease (AD), including lecanemab and donanemab, require patients to meet specific eligibility criteria for treatment. These criteria define a limited “therapeutic time window,” after which patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Saki Nakashima, Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Kazushi Suzuki, Atsushi Iwata, Tatsushi Toda, Takeshi Iwatsubo, for Alzheimer's Disease Neuroimaging Initiative
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
ADNI
Alzheimer's disease
disease‐modifying therapy
NACC
therapeutic window
Online Access:https://doi.org/10.1002/trc2.70102
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/trc2.70102

Similar Items